Anje Cauwels
Overview
Explore the profile of Anje Cauwels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daneels W, Van Parys A, Huyghe L, Rogge E, De Rouck S, Christiaen R, et al.
Exp Hematol Oncol
. 2024 Jun;
13(1):59.
PMID: 38831452
Type I interferon (IFN) is a potent antitumoral drug, with an important history in the treatment of hematologic malignancies. However, its pleiotropic nature leads to severe dose-limiting toxicities that blunt...
2.
Van Lint S, Van Parys A, Van Den Eeckhout B, Vandamme N, Plaisance S, Verhee A, et al.
Mol Cancer
. 2023 Nov;
22(1):191.
PMID: 38031106
Despite major improvements in immunotherapeutic strategies, the immunosuppressive tumor microenvironment remains a major obstacle for the induction of efficient antitumor responses. In this study, we show that local delivery of...
3.
Van Den Eeckhout B, Huyghe L, Van Lint S, Burg E, Plaisance S, Peelman F, et al.
J Immunother Cancer
. 2021 Nov;
9(11).
PMID: 34772757
Background: Clinical success of therapeutic cancer vaccines depends on the ability to mount strong and durable antitumor T cell responses. To achieve this, potent cellular adjuvants are highly needed. Interleukin-1β...
4.
Wijnands K, Meesters D, Vandendriessche B, Briede J, van Eijk H, Brouckaert P, et al.
Int J Mol Sci
. 2021 Nov;
22(21).
PMID: 34769369
Competition for the amino acid arginine by endothelial nitric-oxide synthase (NOS3) and (pro-)inflammatory NO-synthase (NOS2) during endotoxemia appears essential in the derangement of the microcirculatory flow. This study investigated the...
5.
Cauwels A, Van Lint S, Rogge E, Verhee A, Van Den Eeckhout B, Pang S, et al.
Sci Rep
. 2021 Nov;
11(1):21575.
PMID: 34732771
Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN...
6.
Goossens S, Cauwels A, Pieters T, De Smedt R, TSas S, Almeida A, et al.
Haematologica
. 2021 Oct;
107(6):1448-1453.
PMID: 34647441
No abstract available.
7.
Awad R, Lecocq Q, Zeven K, Ertveldt T, De Beck L, Ceuppens H, et al.
Mol Ther Methods Clin Dev
. 2021 Sep;
22:172-182.
PMID: 34485603
Monoclonal antibodies that target the inhibitory immune checkpoint axis consisting of programmed cell death protein 1 (PD-1) and its ligand, PD-L1, have changed the immune-oncology field. We identified K2, an...
8.
Cauwels A, Tavernier J
Front Immunol
. 2020 Jun;
11:674.
PMID: 32477325
Autoimmune diseases such as multiple sclerosis (MS), type I diabetes (T1D), inflammatory bowel diseases (IBD), and rheumatoid arthritis (RA) are chronic, incurable, incapacitating and at times even lethal conditions. Worldwide,...
9.
Huyghe L, Van Parys A, Cauwels A, Van Lint S, De Munter S, Bultinck J, et al.
EMBO Mol Med
. 2020 Jan;
12(2):e11223.
PMID: 31912630
Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity-on-Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index....
10.
Cauwels A, Van Lint S, Catteeuw D, Pang S, Paul F, Rogge E, et al.
J Autoimmun
. 2018 Nov;
97:70-76.
PMID: 30467068
Type I Interferon (IFN) is widely used for multiple sclerosis (MS) treatment, but its side effects are limiting and its mechanism of action still unknown. Furthermore, 30-50% of MS patients...